The Filing Desk

Orchestra BioMed

OBIO · Nasdaq · Health Care · Financials, fiscal 2021 to 2025

OBIO · Last close · November 19, 2026
$7.00
Value Orchestra BioMed yourself

Orchestra BioMed's revenue rose 1169.2% to $34 million in fiscal 2025. Its operating margin was −154.7%, up from −2,437.5% a year earlier. Free cash flow was −$49 million. The diluted share count rose 29.7%.

Orchestra BioMed Holdings, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 12, 2026 · 0001104659-26-026754 Updated
Revenue
$34M
1169.2%
Operating margin
−154.7%
2282.8 pts
Net income
−$53M
 
Free cash flow
−$49M
 
Return on equity
−121.8%
1.0 pts
Market cap
$452M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Orchestra BioMed does

Orchestra BioMed is a biomedical company that develops heart and blood vessel treatments with partners that are large medical device makers. It was formed in 2018 around a set of late-stage product candidates from its founders. It has no approved products and has limited sources of revenue.

Its two flagship candidates are Atrioventricular Interval Modulation Therapy, or AVIM, for high blood pressure, and Virtue Sirolimus AngioInfusion Balloon, a drug-delivering balloon for clogged arteries. AVIM works as a software update to a standard cardiac pacemaker. It has an exclusive license and collaboration agreement with Medtronic to develop and sell AVIM for uncontrolled high blood pressure in patients who need a pacemaker, and a pivotal study called BACKBEAT is enrolling patients.

For Virtue, it has started enrolling patients in a U.S. pivotal trial, which compares it with Boston Scientific's AGENT drug-coated balloon for blocked stents. The company says it shares risks and rewards with its partners.

Its biggest risks, as it describes them

  • It has lost money since it began and may never be profitable.
  • It may need substantial additional funding to continue developing its products.
  • Its clinical studies could fail or be delayed, which could stop its devices from being approved.
  • It depends on partners such as Medtronic to develop and sell its products.
  • It competes with much larger companies.
From Orchestra BioMed's annual report on Form 10-K, filed March 12, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Orchestra BioMed lost money in fiscal 2025: a net loss of $53 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments2848867106
Debt incl. finance leases———1515
Net debt (negative means net cash)———−52−92
Net debt to EBITDA—————
Debt to equity———0.5x0.3x
Interest coverage—−25.1x−36.8x−216.5x−35.8x
Current ratio10.9x4.6x8.0x4.3x6.5x
Quick ratio10.9x4.5x7.9x4.3x6.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Orchestra BioMed's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $259,541 of Orchestra BioMed shares on the open market, and 2 insiders sold $257,682, $257,550 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 3, 2026David P HochmanSee Remarks, DirectorBought10,000$4.79$47,900Form 4
Sep 1, 2026Darren ShermanSee Remarks, DirectorSold plan15,000$4.94$74,100Form 4
Aug 26, 2026Darren ShermanSee Remarks, DirectorBought2,000$5.33$10,660Form 4
Aug 3, 2026Darren ShermanSee Remarks, DirectorSold plan15,000$4.09$61,350Form 4
Jul 1, 2026Darren ShermanSee Remarks, DirectorSold plan15,000$4.27$64,050Form 4
Jun 1, 2026Darren ShermanSee Remarks, DirectorSold plan15,000$3.87$58,050Form 4
Jun 1, 2026David P HochmanSee Remarks, DirectorBought5,000$3.83$19,150Form 4
May 18, 2026Jason AryehDirectorBought665$3.75$2,494Form 4
May 15, 2026Jason AryehDirectorBought8,971$3.90$34,987Form 4
May 15, 2026David P HochmanSee Remarks, DirectorBought5,000$3.77$18,850Form 4
May 14, 2026Eric S FainDirectorBought20,000$4.13$82,600Form 4
Apr 27, 2026Rtw Investments Lp10% ownerSold32$4.13$132Form 4
The latest 12 of 13 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score——5 of 9
Rule of 40−1,696.0%−1,931.9%1,021.5%
Altman Z''−4.16−13.57−7.02
Accruals ratio−3.1%−12.2%−3.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets——Pass
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin roseFailFailPass
Revenue rose relative to assetsPassFailPass
F-score——5 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Orchestra BioMed side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Orchestra BioMedFY251,169.2%−154.7%−147.7%——5
StereotaxisFY2520.3%−68.3%−42.5%———Compare
electroCoreFY2527.2%−41.1%−25.8%———Compare
SenseonicsFY2556.9%−193.8%−170.9%——4Compare
Precision Optics CorporationFY2665.2%−11.1%−6.3%−22.8%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

5 years of figures

Fiscal yearFY21FY22FY23FY24FY25
Income statement
Revenue—43334
Revenue growth——−21.9%−4.4%1,169.2%
Gross profit—33233
Research and development—22344358
Operating income−0−33−52−64−52
Net income−0−34−49−61−53
Diluted EPS (US$)−0.02−2.24−1.48−1.66−1.11
Diluted shares (millions)2015333748
Cash flow
Cash from operations−0−29−46−51−49
Capital expenditure—1000
Free cash flow—−30−46−51−49
Dividends paid020000
Share buybacks00000
Acquisitions00000
Stock-based compensation—381112
Balance sheet at fiscal year end
Cash and short-term investments2848867106
Debt incl. finance leases———1515
Total assets162969576115
Total liabilities643274352
Shareholders' equity−4−7683354
Margins and ratios
Gross margin—94.0%93.3%92.3%99.4%
Operating margin—−924.3%−1,866.2%−2,437.5%−154.7%
Net margin—−951.3%−1,779.7%−2,313.3%−157.4%
Free cash flow margin—−845.7%−1,674.1%−1,927.5%−147.7%
Rule of 40 (growth + FCF margin)——−1,696.0%−1,931.9%1,021.5%
Return on capital—————
Return on equity——−160.8%−120.8%−121.8%
Return on assets—−26.1%−51.5%−71.2%−55.2%
Net debt to EBITDA—————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Orchestra BioMed's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Orchestra BioMed.